By Vince Sullivan ( May 6, 2019, 4:01 PM EDT) -- Takeda Pharmaceutical Co. objected Monday to the proposed Chapter 11 liquidation plan of Orexigen Therapeutics Inc., saying it didn't have the chance to opt out of third-party releases that would hamper its defenses should the debtor pursue up to $6 million in claims post-confirmation....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.